Truro News

A new front in war against superbugs

N.S. researcher on trail of chemicals released in bacterial ghts

- BY JOHN MCPHEE

EDITOR’S NOTE: is is the rst in a week-long series on the rise of the superbugs around the world. Watch for it in the newspaper and extended, interactiv­e version each day on our website. For more coverage see page B5.

Clarissa Sit dedicates her workday to nding new ways to battle infections that have become resistant to existing antibiotic­s.

The importance of this work took a tragic turn into the chemist’s personal life last year with the death of her younger brother.

Matthew, 24, developed Clostridiu­m difficile while in hospital shortly before he died, Sit recounted in an interview at her lab at Saint Mary’s University in Halifax.

As a person with special needs, Matthew dealt with many medical issues, so he was particular­ly susceptibl­e to that virulent intestinal infection, she said.

e doctors tried several types of antibiotic­s until nally Matthew was put on Vancomycin, “which is what we call the drug of last resort,” Sit said. “By the time things sorted themselves out, he was su ering from major in ammation.”

The decreasing effectiven­ess of these kinds of antimicrob­ial drugs has led to a spike in deaths related to bacterial infections.

According to the Canadian Patient Safety Institute, about 220,000 Canadians develop infections such as C. di cile and MRSA ( methicilli­n- resistant staphyloco­ccus aureus) each year resulting in at least 8,000 deaths.

e problem can be traced to the overuse of antibiotic­s and the ability of bacteria to nd ways to survive their attack, Sit said.

Compoundin­g the problem, the pharmaceut­ical industry doesn’t put much e ort into developing new antibiotic­s these days because it’s not much of a money-maker.

eir rationale is ‘it’s better we nd things that treat heart disease, something that somebody has to take every day for the rest of their lives, then that’s guaranteed income,” Sit said, as opposed to an antibiotic that only has to be taken for 10 days.

As a chemist with a background in microbiolo­gy, Sit is attacking the superbug problem by studying the chemical reactions that result from pitting two types of bacteria against each other.

“We’ll take two completely pure strains and then force them to grow in the same space,” said Sit, who was awarded a $171,000 grant last year from the federal government’s Canada Foundation for Innovation’s John R. Evans Leaders Fund. “ ey generally don’t like that. ey’ll produce molecules, chemicals, that are designed to send the competitor o . ... Once we gure out what those are, we want to evaluate, can those be useful antibiotic­s or some sort of drug to treat infections and things like that?”

While deadly outbreaks do occur in Atlantic Canada, such as the 11 c. di cile-related deaths at Cape Breton hospitals in 2011 – superbug rates in hospitals are lower in this region compared to central and western Canada.

For example, in 2015, there were 2.91 cases of c. di cile per 1,000 patient admissions in 2015 in Atlantic Canada, compared to 3.43 in Ontario and Quebec and 3.45 in western provinces.

“We’ve been fortunate in the rates of resistance, historical­ly, we’ve had less resistance here compared to other centres,” said Dr. Paul Bonnar, an infectious disease physician in Halifax.

It’s not known exactly why that’s the case, although Bonnar said our relatively small population and lower immigratio­n rates might be at play.

“But all of that is changing, certainly as population­s grows and more invasive procedures, more antibiotic use, more travel internatio­nally and immigratio­n all adds to a change in the resistance patterns,” said Bonnar, who is colead of the Nova Scotia Health Authority’s Antimicrob­ial Stewardshi­p program.

The stewardshi­p program was establishe­d last year to monitor the number of antibiotic prescripti­ons in the province, with an eye to reducing the antibiotic overuse that allows bacteria to become drugresist­ant.

“The more effective interventi­ons are reviewing antimicrob­ials and given some feedback to prescriber­s on how they can optimize their antibiotic use,” Bonnar said. “That takes up most of our time… People have been very receptive to that feedback. Everybody wants to do what’s best for their patients and if we can help them optimize their antibiotic use, that’s going to improve patient outcomes.”

A national patient advocacy group said more must be done given the impact of drug-resistant infections.

“I would say from a patient’s perspectiv­e, we can always do more,” said Anne Maclaurin, the patient safety improvemen­t lead for the Canadian Patient Safety Institute, said from the CPSI’S offices in Edmonton. “It’s very traumatic to the patient, detrimenta­l and we could always do more and do better.”

For example, there should be a consistent standard across the country for how we measure infection rates.

“There’s not one single thing,” Maclaurin said. “Leadership making it a priority, good measuremen­t surveillan­ce systems in place, resources right at the facility level. From an individual health-care provider, things like good hand hygiene practices would be things you’d be looking at.”

Concerns have long been raised across Canada, including Atlantic Canada, that hospital staff don’t wash their hands when they should.

A monitoring project in Cape Breton in 2012 revealed that handwashin­g rates among hospital staff reached up to 100 per cent when staff knew they were being watched; the rate dropped to 60 per cent during undisclose­d surveillan­ce, with the worst offenders bing doctors.

New Brunswick Auditor General Kim Macpherson uncovered a similar problem in that province in 2015.

But Bonnar said he believes handwashin­g rates are improving in hospitals.

“As a recent graduate, it’s a heavy focus of my training and the medical schools,” he said. “it does speak to the difficulty of changing behaviour so just changing the routine of health-care workers.”

Back at Saint Mary’s, Clarissa Sit said it’s critical that government, academic institutio­ns and private interests such as the pharmaceut­ical industry put more resources tackling the problem of drug-resistant disease.

Since losing her brother last year, Sit’s passion for the work burns brighter than ever.

“Watching him go through that process definitely reaffirms that I’m doing the right line of work for me. Now I have the extra motivation because it’s like, he’s got to have a legacy and his legacy is how he touched other lives.”

 ??  ?? Clarissa Sit, left, assistant professor in chemistry at Saint Mary’s University, looks for antifungal compounds that are produced by bacteria with senior undergradu­ate student Kaitlyn Blatt-janmaat inside a SMU research lab recently.
Clarissa Sit, left, assistant professor in chemistry at Saint Mary’s University, looks for antifungal compounds that are produced by bacteria with senior undergradu­ate student Kaitlyn Blatt-janmaat inside a SMU research lab recently.

Newspapers in English

Newspapers from Canada